Literature DB >> 18387720

A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2.

Takao Tsuji1, Takeshi Shimizu, Keiko Sasaki, Kentaro Tsukamoto, Hideyuki Arimitsu, Sadayuki Ochi, Toshiyasu Shimizu, Koki Taniguchi, Masatoshi Noda, Paola Neri, Hiroshi Mori.   

Abstract

Enterohemorrhagic Escherichia coli (EHEC) produces Stx1 and Stx2 causing severe diseases. Their B-subunits (StxBs) exhibit low immunogenicity and the anti-StxB antibodies neutralizing both Stxs has not been prepared yet. By intranasal vaccination with His-tagged-StxB (Stx1B-His or Stx2B-His) plus a mutant heat-labile enterotoxin (mLT) in mice, their serum and lung fluid reacted with appropriate StxB. Mice vaccinated with Stx2B-His plus mLT had antibodies reacting Stx1B and showed the resistance to toxemia of Stx1 and Stx2. This is the first demonstration to get anti-Stx2B serum neutralizing both Stxs. These suggest that the nasal vaccination with Stx2B-His and mLT is effective for preventing toxemias by EHEC.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18387720     DOI： 10.1016/j.vaccine.2008.02.034

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  9 in total

1.  Nano-multilamellar lipid vesicles (NMVs) enhance protective antibody responses against Shiga toxin (Stx2a) produced by enterohemorrhagic Escherichia coli strains (EHEC).

Authors:  M J Rodrigues-Jesus; W L Fotoran; R M Cardoso; K Araki; G Wunderlich; Luís C S Ferreira
Journal:  Braz J Microbiol       Date:  2018-12-06       Impact factor: 2.476

Review 2.  Will there ever be a universal Staphylococcus aureus vaccine?

Authors:  Gerald B Pier
Journal:  Hum Vaccin Immunother       Date:  2013-06-21       Impact factor: 3.452

3.  Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice.

Authors:  Jun Fujii; Mariko Naito; Takashi Yutsudo; Sohkichi Matsumoto; Daniel P Heatherly; Takeshi Yamada; Hideyuki Kobayashi; Shin-Ichi Yoshida; Tom Obrig
Journal:  Clin Vaccine Immunol       Date:  2012-10-03

4.  Evaluation of Fab and F(ab')2 fragments and isotype variants of a recombinant human monoclonal antibody against Shiga toxin 2.

Authors:  Donna E Akiyoshi; Abhineet S Sheoran; Curtis M Rich; L Richard; Susan Chapman-Bonofiglio; Saul Tzipori
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

Review 5.  Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection.

Authors:  Victor A Garcia-Angulo; Anjana Kalita; Alfredo G Torres
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

Review 6.  Treatment Strategies for Infections With Shiga Toxin-Producing Escherichia coli.

Authors:  Sabrina Mühlen; Petra Dersch
Journal:  Front Cell Infect Microbiol       Date:  2020-05-06       Impact factor: 5.293

Review 7.  Role of Recent Therapeutic Applications and the Infection Strategies of Shiga Toxin-Producing Escherichia coli.

Authors:  Su-Bin Hwang; Ramachandran Chelliah; Ji Eun Kang; Momna Rubab; Eric Banan-MwineDaliri; Fazle Elahi; Deog-Hwan Oh
Journal:  Front Cell Infect Microbiol       Date:  2021-06-29       Impact factor: 5.293

8.  Evaluation of recombinant forms of the shiga toxin variant Stx2eB subunit and non-toxic mutant Stx2e as vaccine candidates against porcine edema disease.

Authors:  Toshio Sato; Takeshi Matsui; Eiji Takita; Yumiko Kadoyama; Sou-Ichi Makino; Ko Kato; Kazutoshi Sawada; Takashi Hamabata
Journal:  J Vet Med Sci       Date:  2013-07-03       Impact factor: 1.267

9.  Protection from hemolytic uremic syndrome by eyedrop vaccination with modified enterohemorrhagic E. coli outer membrane vesicles.

Authors:  Kyoung Sub Choi; Sang-Hyun Kim; Eun-Do Kim; Sang-Ho Lee; Soo Jung Han; Sangchul Yoon; Kyu-Tae Chang; Kyoung Yul Seo
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.